Abstract
Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Current Proteomics
Title: How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Volume: 1 Issue: 1
Author(s): Scott D. Patterson
Affiliation:
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Abstract: Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Export Options
About this article
Cite this article as:
Patterson D. Scott, How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?, Current Proteomics 2004; 1 (1) . https://dx.doi.org/10.2174/1570164043488306
DOI https://dx.doi.org/10.2174/1570164043488306 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiproliferative and Genotoxic Action of an Underexploited Organoteluran Derivative on Sarcoma 180 Cells
Anti-Cancer Agents in Medicinal Chemistry Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advancements in the Treatment and Repair of Tendon Injuries
Current Tissue Engineering (Discontinued) Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
Current Cancer Drug Targets EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]
Current Cancer Drug Targets High-Throughput Miniaturized Immunoassay for Human Interleukin-6 Using Electrochemical Sandwich-Type Enzyme Immunosensors
Current Pharmaceutical Analysis Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
Current Pharmaceutical Design